Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.44 |
| ▸ | ABAT | P80404 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19218160 | 1.00 | CYP2A6 (0.44) | CYP2A6HSD17B10ALDH5A1ABATESR2 | |
| SCHEMBL2320728 | 0.93 | NPC1 (0.47) | CYP2A6HSD17B10ALDH5A1ABATESR2 | |
| SCHEMBL3243130 | 0.93 | ESR2 (0.46) | CYP2A6HSD17B10ALDH5A1ABATESR2 | |
| SCHEMBL3438249 | 0.91 | HDAC1 (0.46) | CYP2A6HSD17B10ALDH5A1ABATESR2 | |
| SCHEMBL14026786 | 0.89 | ESR2 (0.37) | CYP2A6HSD17B10ALDH5A1ABATESR2 | |
| SCHEMBL30226 | 0.89 | ESR2 (0.57) | CYP2A6HSD17B10ALDH5A1ABATESR2 | |
| SCHEMBL7792619 | 0.89 | ESR2 (0.57) | CYP2A6HSD17B10ALDH5A1ABATESR2 | |
| SCHEMBL10740141 | 0.89 | HTT (0.44) | ESR2ALDH1A1TRIM24TRIM33KDM4E | |
| SCHEMBL11678689 | 0.89 | HTT (0.44) | ESR2ALDH1A1TRIM24TRIM33KDM4E | |
| SCHEMBL547869 | 0.89 | HTT (0.44) | ESR2ALDH1A1TRIM24TRIM33KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448360-B2 | Synthesis method for preparing SGLT inhibitor intermediate | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-10-21 | — | — | US | claimed |
| EP-4212520-B1 | SYNTHESIS METHOD FOR PREPARING SGLT INHIBITOR INTERMEDIATES | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2025-08-13 | — | — | EP | claimed |
| US-20230322699-A1 | SYNTHESIS METHOD FOR PREPARING SGLT INHIBITOR INTERMEDIATE | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2023-10-12 | — | — | US | claimed |
| EP-4212520-A1 | SYNTHESIS METHOD FOR PREPARING SGLT INHIBITOR INTERMEDIATE | Daewoong Pharmaceutical Co., Ltd. (KR) | 2023-07-19 | — | — | EP | claimed |
| CN-112094253-B | Synthetic method for preparing SGLT inhibitor intermediate | 株式会社大熊制药 | 2023-01-10 | — | — | CN | claimed |
| WO-2022051980-A1 | SYNTHESIS METHOD FOR PREPARING SGLT INHIBITOR INTERMEDIATE | 广东莱佛士制药技术有限公司 | 2022-03-17 | — | — | WO | claimed |
| CN-112094253-A | Synthetic method for preparing SGLT inhibitor intermediate | 广东莱佛士制药技术有限公司 | 2020-12-18 | — | — | CN | claimed |
| US-4582903-A | Synthesis of unsaturated hydantoins with an inexpensive catalyst | STAUFFER CHEMICAL COMPANY (US) | 1986-04-15 | — | — | US | claimed |
| US-4345072-A | Process for the production of 5-arylidene hydantoins (B) | DEGUSSA AG (DE) | 1982-08-17 | — | — | US | claimed |
| EP-4103557-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-12-23 | — | — | US | disclosed |
| US-12448360-B2 | Synthesis method for preparing SGLT inhibitor intermediate | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-10-21 | — | — | US | disclosed |
| US-12448360-B2 | Synthesis method for preparing SGLT inhibitor intermediate | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-10-21 | — | — | US | disclosed |
| EP-4212520-B1 | SYNTHESIS METHOD FOR PREPARING SGLT INHIBITOR INTERMEDIATES | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2025-08-13 | — | — | EP | disclosed |
| US-4248873-A | Nitro-substituted 1,4-dihydropyridines, processes for _their production and their medicinal use | BAYER AKTIENGESELLSCHAFT (DE) | 1981-02-03 | — | — | US | disclosed |
| EP-0012180-A1 | 1,4-Dihydropyridine compounds, their preparation, pharmaceutical compositions containing said compounds and preparation of these compositions | BAYER AG (DE) | 1980-06-25 | — | — | EP | disclosed |
| US-4179500-A | 1,4-Dihydropyridine-sugar derivatives, and their use as medicaments | BAYER AKTIENGESELLSCHAFT (DE) | 1979-12-18 | — | — | US | disclosed |
| EP-0002208-A1 | Nitro 1,4-dihydropyridines, medicaments containing them and their manufacture | BAYER AG (DE) | 1979-06-13 | — | — | EP | disclosed |
| EP-0001769-A1 | Sulfur-containing esters of 1,4-dihydropyridine carboxylic acids, their preparation and pharmaceutical use | BAYER AG (DE) | 1979-05-16 | — | — | EP | disclosed |
| US-4044141-A | CORONARY DILATING, SPASMOLYTIC, HYPOTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448360-B2 | Synthesis method for preparing SGLT inhibitor intermediate | SLC5A2, SLC5A1, SLC2A1 | CYP2A6 263/4885HSD17B10 1065/4885ALDH5A1 687/4885 |
| US-20230322699-A1 | SYNTHESIS METHOD FOR PREPARING SGLT INHIBITOR INTERMEDIATE | SLC5A2, SLC5A1, SLC2A1 | CYP2A6 263/4885HSD17B10 1065/4885ALDH5A1 687/4885 |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | LIPC, LPL, MGLL | CYP2A6 683/4885HSD17B10 68/4885ALDH5A1 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.